BacMam Expressing Highly Glycosylated Porcine Interferon Alpha Induces Robust Antiviral and Adjuvant Effects against Foot-and-Mouth Disease Virus in Pigs
- 22 June 2022
- journal article
- research article
- Published by American Society for Microbiology in Journal of Virology
- Vol. 96 (12), e0052822
- https://doi.org/10.1128/jvi.00528-22
Abstract
Early inhibition of foot-and-mouth disease (FMD) virus (FMDV) replication in pigs is highly desirable as FMDV transmission and shedding rates are higher in pigs than in cattle. However, commercial FMD vaccines require at least 4 to 7 days postvaccination (dpv) for protection, and animals are vulnerable to heterologous viruses before acquiring high antibody levels after the second vaccination. Foot-and-mouth disease (FMD) is an acute contagious disease that affects cloven-hoofed animals and has severe global economic consequences. FMD is most commonly controlled by vaccination. Currently available commercial FMD vaccines contain chemically inactivated whole viruses, which are thought to be slow acting as they are effective only 4 to 7 days following vaccination. Hence, the development of a novel rapid vaccine or alternative measures, such as antiviral agents or the combination of vaccines and antiviral agents for prompt FMD virus (FMDV) outbreak containment, is desirable. Here, we constructed a recombinant baculovirus (BacMam) expressing consensus porcine interferon alpha (IFN-alpha) that has three additional N-glycosylation sites driven by a cytomegalovirus immediate early (CMV-IE) promoter (Bac-Con3N IFN-alpha) for protein expression in mammalian cells. Bac-Con3N IFN-alpha expressing highly glycosylated porcine IFN-alpha protein increased the duration of antiviral effects. We evaluated the antiviral effects of Bac-Con3N IFN-alpha in swine cells and mice and observed sustained antiviral effects in pig serum; additionally, Bac-Con3N IFN-alpha exhibited sustained antiviral effects in vivo as well as adjuvant effects in combination with an inactivated FMD vaccine. Pigs injected with a combination of Bac-Con3N IFN-alpha and the inactivated FMD vaccine were protected against FMDV at 1, 3, and 7 days postvaccination. Furthermore, we observed that in combination with the inactivated FMD vaccine, Bac-Con3N IFN-alpha increased neutralizing antibody levels in mice and pigs. Therefore, we suggest that Bac-Con3N IFN-alpha is a strong potential antiviral and adjuvant candidate for use in combination with inactivated FMD vaccines to protect pigs against FMDV. IMPORTANCE Early inhibition of foot-and-mouth disease (FMD) virus (FMDV) replication in pigs is highly desirable as FMDV transmission and shedding rates are higher in pigs than in cattle. However, commercial FMD vaccines require at least 4 to 7 days postvaccination (dpv) for protection, and animals are vulnerable to heterologous viruses before acquiring high antibody levels after the second vaccination. Therefore, the development of antiviral agents for use in combination with FMD vaccines is essential. We developed a novel antiviral and immunostimulant, Bac-Con3N IFN-alpha, which is a modified porcine IFN-alpha-expressing recombinant baculovirus, to improve IFN stability and allow its direct delivery to animals. We present a promising candidate for use in combination with inactivated FMD vaccines as pigs applied to the strategy had early protection against FMDV at 1 to 7 dpv, and their neutralizing antibody levels were higher than those in pigs administered the vaccine only.Keywords
Funding Information
- Animal and Plant Quarantine Agency
This publication has 68 references indexed in Scilit:
- Baculovirus GP64-Mediated Entry into Mammalian CellsJournal of Virology, 2012
- A pH-Sensitive Heparin-Binding Sequence from Baculovirus gp64 Protein Is Important for Binding to Mammalian Cells but Not to Sf9 Insect CellsJournal of Virology, 2012
- Use of Recombinant Adenovirus Vectored Consensus IFN-α to Avert Severe Arenavirus InfectionPLOS ONE, 2011
- IFN-α produced by human plasmacytoid dendritic cells enhances T cell-dependent naïve B cell differentiationJournal of Leukocyte Biology, 2011
- Regulation of Antitumor Immune Responses by the IL-12 Family Cytokines, IL-12, IL-23, and IL-27Journal of Immunology Research, 2010
- Acquisition of Complement Resistance through Incorporation of CD55/Decay-Accelerating Factor into Viral Particles Bearing Baculovirus GP64Journal of Virology, 2010
- Potential Benefits of Sequential Inhibitor-Mutagen Treatments of RNA Virus InfectionsPLoS Pathogens, 2009
- Effects of glycosylation on the stability of protein pharmaceuticalsJournal of Pharmaceutical Sciences, 2009
- Enhanced Antiviral Activity against Foot-and-Mouth Disease Virus by a Combination of Type I and II Porcine InterferonsJournal of Virology, 2007
- Baculovirus as versatile vectors for protein expression in insect and mammalian cellsNature Biotechnology, 2005